688331 荣昌生物
已收盘 08-23 15:00:00
资讯
新帖
简况
港股异动 | 荣昌生物(09995)午后跌超6% 上半年亏损扩大逾10% 机构上调未来三年净亏损预测
智通财经 · 08-23 15:32
港股异动 | 荣昌生物(09995)午后跌超6% 上半年亏损扩大逾10% 机构上调未来三年净亏损预测
荣昌生物(09995)下跌5.12%,报11.86元/股
金融界 · 08-23 11:06
荣昌生物(09995)下跌5.12%,报11.86元/股
荣昌生物08月22日遭主力抛售964万元 环比增加2310.00%
市场透视 · 08-22 15:18
荣昌生物08月22日遭主力抛售964万元 环比增加2310.00%
港股异动 | 荣昌生物(09995)再跌超8% 上半年亏损扩大至7.8亿元 机构下调产品峰值销售额预测
智通财经 · 08-22
港股异动 | 荣昌生物(09995)再跌超8% 上半年亏损扩大至7.8亿元 机构下调产品峰值销售额预测
荣昌生物(09995)下跌5.71%,报13.22元/股
金融界 · 08-22
荣昌生物(09995)下跌5.71%,报13.22元/股
“ADC一哥”营收大涨76%
药智网 · 08-21
“ADC一哥”营收大涨76%
生物科技概念盘中拉升,荣昌生物涨1.74%
自选股智能写手 · 08-21
生物科技概念盘中拉升,荣昌生物涨1.74%
荣昌生物(688331)8月20日主力资金净卖出385.89万元
证券之星 · 08-21
荣昌生物(688331)8月20日主力资金净卖出385.89万元
荣昌生物踩了脚刹车
并购菁英汇 · 08-20
荣昌生物踩了脚刹车
国信证券发布荣昌生物研报,核心产品销售快速增长,新适应症持续开拓
每日经济新闻 · 08-20
国信证券发布荣昌生物研报,核心产品销售快速增长,新适应症持续开拓
浦银国际证券:给予荣昌生物中性评级,目标价位35.0元
证券之星 · 08-20
浦银国际证券:给予荣昌生物中性评级,目标价位35.0元
浦银国际证券给予荣昌生物持有评级 2Q24泰它西普销售略好于预期 但研发费用高于预期
每日经济新闻 · 08-20
浦银国际证券给予荣昌生物持有评级 2Q24泰它西普销售略好于预期 但研发费用高于预期
【港股通】荣昌生物(09995)跌超3% 交银国际削其目标价57.1%
金吾财讯 · 08-20
【港股通】荣昌生物(09995)跌超3% 交银国际削其目标价57.1%
港股异动 | 荣昌生物(09995)跌超3% 上半年亏损同比扩大11% 货币资金减少至6.73亿元
智通财经网 · 08-20
港股异动 | 荣昌生物(09995)跌超3% 上半年亏损同比扩大11% 货币资金减少至6.73亿元
荣昌生物(688331):商业化产品快速放量 核心管线高效推进
广发证券股份有... · 08-20
荣昌生物(688331):商业化产品快速放量 核心管线高效推进
荣昌生物(688331):收入符合预期 核心品种适应症持续拓展
西南证券股份有... · 08-20
荣昌生物(688331):收入符合预期 核心品种适应症持续拓展
【交银国际:维持荣昌生物“买入”评级 目标价下调至24港元】金十数据8月20日讯,交银国际发表研究报告称,维持荣昌生物(09995.
美港电讯 · 08-20
【交银国际:维持荣昌生物“买入”评级 目标价下调至24港元】金十数据8月20日讯,交银国际发表研究报告称,维持荣昌生物(09995.
招银证券:给予荣昌生物(09995.HK)“增持”评级 目标价19.59港元
同花顺金融研究... · 08-20
招银证券:给予荣昌生物(09995.HK)“增持”评级 目标价19.59港元
交银国际:维持荣昌生物(09995)“买入”评级 目标价下调至24港元
智通财经 · 08-20
交银国际:维持荣昌生物(09995)“买入”评级 目标价下调至24港元
【券商聚焦】交银国际削荣昌生物(09995)目标价57.1% 维持买入评级
金吾财讯 · 08-20
【券商聚焦】交银国际削荣昌生物(09995)目标价57.1% 维持买入评级
公司概况
公司名称:
荣昌生物制药(烟台)股份有限公司
所属行业:
医药制造业
上市日期:
2022-03-31
主营业务:
荣昌生物制药(烟台)股份有限公司是一家具有全球化视野的创新型生物制药企业,自成立以来一直专注于抗体药物偶联物(ADC)、抗体融合蛋白、单抗及双抗等治疗性抗体药物领域。公司主营业务是发现、开发与商业化创新、有特色的同类首创(first-in-class)与同类最佳(best-in-class)生物药,以创造药物临床价值为导向,为自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域提供安全、有效、可及的临床解决方案,以满足大量尚未被满足的临床需求。公司的核心产品为泰它西普、维迪西妥单抗、RC28。
发行价格:
48.00
{"stockData":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":24.2,"timestamp":1724396400000,"preClose":25.35,"halted":0,"volume":3832934,"delay":0,"floatShares":162000000,"shares":544000000,"eps":-2.918,"marketStatus":"已收盘","marketStatusCode":5,"change":-1.15,"latestTime":"08-23 15:00:00","open":25.21,"high":25.32,"low":24.14,"amount":94360000,"amplitude":0.0465,"askPrice":24.2,"askSize":4,"bidPrice":24.19,"bidSize":129,"shortable":0,"etf":0,"ttmEps":-2.918,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724635800000},"adr":0,"adjPreClose":25.35,"symbolType":"stock_kcb","openAndCloseTimeList":[[1724376600000,1724383800000],[1724389200000,1724396400000]],"highLimit":27.89,"lowLimit":22.82,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":544332083,"pbRate":4.94,"roa":"--","roe":"--","epsLYR":-2.8,"committee":0.223529,"marketValue":13173000000,"floatMarketCap":3919000000,"peRate":-8.293352,"changeRate":-0.0454,"turnoverRate":0.0237,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2024-08-26。","afterMarket":{"amount":0,"volume":0,"close":24.2,"buyVolume":0,"sellVolume":0,"time":1724398437153,"indexStatus":"已收盘 08-23 15:30:00","preClose":25.35}},"requestUrl":"/m/hq/s/688331/wiki","defaultTab":"wiki","newsList":[{"id":"2461655843","title":"港股异动 | 荣昌生物(09995)午后跌超6% 上半年亏损扩大逾10% 机构上调未来三年净亏损预测","url":"https://stock-news.laohu8.com/highlight/detail?id=2461655843","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461655843?lang=zh_cn&edition=full","pubTime":"2024-08-23 15:32","pubTimestamp":1724398361,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,荣昌生物午后跌超6%,截至发稿,跌4.64%,报11.92港元,成交额3479.43万港元。消息面上,荣昌生物近日发布上半年业绩,收益7.4亿元人民币,同比增加76.5%;股东应占亏损7.8亿元,同比扩大10.96%。截至2024上半年,荣昌生物账上还剩6.73亿元,同比减少近四成。公司表示,有充足的融资储备支持运营至盈亏平衡。目标价由56港元下调至24港元,维持“买入”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1169219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064130708.USD","BK1161","688331","LU2328871848.SGD","BK1583","BK1574","09995","LU2148510915.USD","LU1064131003.USD","LU1969619763.USD","BK0239"],"gpt_icon":0},{"id":"2461133589","title":"荣昌生物(09995)下跌5.12%,报11.86元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2461133589","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461133589?lang=zh_cn&edition=full","pubTime":"2024-08-23 11:06","pubTimestamp":1724382386,"startTime":"0","endTime":"0","summary":"8月23日,荣昌生物(09995)盘中下跌5.12%,截至11:06,报11.86元/股,成交1619.98万元。荣昌生物制药(烟台)股份有限公司的主营业务是发现、开发、生产和商业化同类首创、同类最佳的生物药物,主要针对自身免疫、肿瘤、眼科等重大疾病领域。公司在中国和美国设有实验研究机构和办事处,已创制出一批具有重大临床价值的生物新药。截至2024年中报,荣昌生物营业总收入7.4亿元、净利润-7.8亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/23110642642049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","LU1064131003.USD","LU2328871848.SGD","BK1574","BK1161","LU1064130708.USD","LU2148510915.USD","BK0239","688331","09995","LU1969619763.USD"],"gpt_icon":0},{"id":"2461366333","title":"荣昌生物08月22日遭主力抛售964万元 环比增加2310.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461366333","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461366333?lang=zh_cn&edition=full","pubTime":"2024-08-22 15:18","pubTimestamp":1724311113,"startTime":"0","endTime":"0","summary":"08月22日, 荣昌生物股价跌2.12%,报收25.35元,成交金额7880万元,换手率1.92%,振幅3.98%,量比1.03。荣昌生物今日主力资金净流出964万元,连续3日净流出,上一交易日主力净流出40万元,今日环比增加2310.00%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为64.29%,平均跌幅为3.94%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408221538409f46f0ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408221538409f46f0ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688331","LU2148510915.USD","LU1064130708.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2461336351","title":"港股异动 | 荣昌生物(09995)再跌超8% 上半年亏损扩大至7.8亿元 机构下调产品峰值销售额预测","url":"https://stock-news.laohu8.com/highlight/detail?id=2461336351","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461336351?lang=zh_cn&edition=full","pubTime":"2024-08-22 13:57","pubTimestamp":1724306263,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,荣昌生物(09995)再跌超8%,截至发稿,跌8.42%,报12.84港元,成交额3683.27万港元。消息面上,荣昌生物近日发布上半年业绩,收益7.4亿元人民币,同比增加76.5%;股东应占亏损7.8亿元,同比扩大10.96%。不派中期息。截至2024上半年,荣昌生物账上还剩6.73亿元,同比减少近四成。交银国际发布研报指出,将2024-26年净亏损预测调高至14.8亿/10.4亿/3.4亿元,出于更保守的授权收入及更高的成本费用预测,并将泰它西普和维迪西妥的峰值销售额(含海外)下调至48亿/24亿元。目标价由56港元下调至24港元,维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1168274.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064131003.USD","BK1583","LU2148510915.USD","688331","LU2328871848.SGD","LU1064130708.USD","LU1969619763.USD","BK1161","BK0239","09995","BK1574"],"gpt_icon":0},{"id":"2461033385","title":"荣昌生物(09995)下跌5.71%,报13.22元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2461033385","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461033385?lang=zh_cn&edition=full","pubTime":"2024-08-22 10:07","pubTimestamp":1724292478,"startTime":"0","endTime":"0","summary":"8月22日,荣昌生物(09995)盘中下跌5.71%,截至10:07,报13.22元/股,成交783.5万元。荣昌生物制药(烟台)股份有限公司的主营业务是发现、开发、生产和商业化同类首创、同类最佳的生物药物,主要针对自身免疫、肿瘤、眼科等重大疾病领域。公司在中国和美国设有实验研究机构和办事处,已创制出一批具有重大临床价值的生物新药。截至2024年中报,荣昌生物营业总收入7.4亿元、净利润-7.8亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/22100742591230.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1064130708.USD","LU2328871848.SGD","LU1064131003.USD","LU2148510915.USD","BK1161","LU1969619763.USD","BK0239","BK1583","09995","688331","BK1574"],"gpt_icon":0},{"id":"2461427862","title":"“ADC一哥”营收大涨76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461427862","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461427862?lang=zh_cn&edition=full","pubTime":"2024-08-21 11:00","pubTimestamp":1724209220,"startTime":"0","endTime":"0","summary":"作为国内的“ADC一哥”,近日荣昌生物披露了2024年中期业绩:实现总营收7.42亿元,同比增加75.59%。营收大增75.59%当前,荣昌生物已顺利将两款产品商业化,分别为自身免疫药物泰它西普和抗肿瘤产品维迪西妥单抗。得益于两款产品的强劲销售,2024年上半年,荣昌生物的总营收较去年同期激增75.59%,达到4.22亿元。而研发费用的大幅增加,导致荣昌生物归母净利润同比减少。同时,截至今年6月30日,公司总现金储备为8.76亿元,较去年同期有所减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408211112039f40324e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408211112039f40324e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688331"],"gpt_icon":0},{"id":"2461863467","title":"生物科技概念盘中拉升,荣昌生物涨1.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461863467","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461863467?lang=zh_cn&edition=full","pubTime":"2024-08-21 09:40","pubTimestamp":1724204430,"startTime":"0","endTime":"0","summary":"08月21日,生物科技概念盘中拉升,截至09点40分,生物科技概念整体指数上涨0.57%,报660.010点。从个股上来看,该概念的成分股中,荣昌生物涨1.74%,天坛生物、生物股份、威海广泰涨幅居前。从资金上来看,截止发稿,生物科技概念主力净流入为-2878.94万,其中万孚生物受到资金热捧,主力净流入153.56万;拉长时间线来看,该板块近20日主力资金净流入-5.71亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240821094030942011db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240821094030942011db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688331","BK1574","BK1583","LU2328871848.SGD","LU1969619763.USD","BK1161","09995"],"gpt_icon":0},{"id":"2461521868","title":"荣昌生物(688331)8月20日主力资金净卖出385.89万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461521868","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461521868?lang=zh_cn&edition=full","pubTime":"2024-08-21 08:24","pubTimestamp":1724199898,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月20日收盘,荣昌生物报收于25.93元,下跌3.28%,换手率1.77%,成交量2.86万手,成交额7451.13万元。8月20日的资金流向数据方面,主力资金净流出385.89万元,占总成交额5.18%,游资资金净流出37.62万元,占总成交额0.5%,散户资金净流入423.51万元,占总成交额5.68%。近5日资金流向一览见下表:荣昌生物融资融券信息显示,融资方面,当日融资买入214.04万元,融资偿还469.74万元,融资净偿还255.69万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082100008552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","LU1064130708.USD","LU1969619763.USD","BK1161","LU1064131003.USD","BK1583","LU2148510915.USD","LU2328871848.SGD","BK0239","09995","BK1574"],"gpt_icon":0},{"id":"2460079110","title":"荣昌生物踩了脚刹车","url":"https://stock-news.laohu8.com/highlight/detail?id=2460079110","media":"并购菁英汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460079110?lang=zh_cn&edition=full","pubTime":"2024-08-20 18:04","pubTimestamp":1724148266,"startTime":"0","endTime":"0","summary":"在市场等待荣昌生物作出更大变革之际,8月17日公司发布了2024年半年报,给了投资者审视公司变革和发展的一个窗口。销售和管理费用控制层面,荣昌生物在2024H1财报呈现出的数据确实证明了有所改善。截至2024H1,荣昌生物的现金及现金等价物余额为6.76亿元。荣昌生物如今到达这步窘境,BD未达预期是其中一个重要诱因。当然,对于荣昌生物和泰它西普而言并不是没有好消息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082018415495aa8b94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082018415495aa8b94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688331","LU1064130708.USD","LU1064131003.USD","LU2148510915.USD","BK0239","09995"],"gpt_icon":0},{"id":"2460027967","title":"国信证券发布荣昌生物研报,核心产品销售快速增长,新适应症持续开拓","url":"https://stock-news.laohu8.com/highlight/detail?id=2460027967","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460027967?lang=zh_cn&edition=full","pubTime":"2024-08-20 16:47","pubTimestamp":1724143620,"startTime":"0","endTime":"0","summary":"国信证券08月20日发布研报称,给予荣昌生物(688331.SH)优于大市评级。评级理由主要包括:1)核心产品销售持续增长,销售费用率下降;2)泰它西普:新适应症获批上市,海外临床持续推进。风险提示:创新药研发失败或进度低于预期;创新药销售不及预期。AI点评:荣昌生物近一个月获得3份券商研报关注,买入1家,平均目标价为35元。(文章来源:每日经济新闻)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082016525395aa1bd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082016525395aa1bd5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0183","002736","BK0028","LU1064131003.USD","BK0239","LU1064130708.USD","688331","BK0276","LU2148510915.USD","BK0188"],"gpt_icon":0},{"id":"2460802114","title":"浦银国际证券:给予荣昌生物中性评级,目标价位35.0元","url":"https://stock-news.laohu8.com/highlight/detail?id=2460802114","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460802114?lang=zh_cn&edition=full","pubTime":"2024-08-20 16:24","pubTimestamp":1724142262,"startTime":"0","endTime":"0","summary":"浦银国际证券有限公司胡泽宇,阳景近期对荣昌生物进行研究并发布了研究报告《2Q24泰它西普销售略好于预期,但研发费用高于预期》,本报告对荣昌生物给出中性评级,认为其目标价位为35.00元,当前股价为25.93元,预期上涨幅度为34.98%。维持“持有”评级及目标价。最新盈利预测明细如下:该股最近90天内共有6家机构给出评级,买入评级5家,中性评级1家;过去90天内机构目标均价为46.76。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082000025664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","09995","688331"],"gpt_icon":0},{"id":"2460214026","title":"浦银国际证券给予荣昌生物持有评级 2Q24泰它西普销售略好于预期 但研发费用高于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2460214026","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460214026?lang=zh_cn&edition=full","pubTime":"2024-08-20 15:58","pubTimestamp":1724140723,"startTime":"0","endTime":"0","summary":"浦银国际证券08月20日发布研报称,给予荣昌生物(688331.SH)持有评级。评级理由主要包括:1)2Q24收入略超我们预期,但净亏损显著高于我们预期;2)泰它西普上半年实现3.8亿元销售额,略好于我们先前预期;3)RC18两个国际临床三期试验均于下半年开始首例患者入组,我们保守预测下半年研发费用将较上半年有所增加。风险提示:出海授权延误或失败、现金流消耗大于预期、销售未如预期、研发延误或临床试验数据不如预期。AI点评:荣昌生物近一个月获得2份券商研报关注,买入1家。文章来源:每日经济新闻原标题:浦银国际证券给予荣昌生物持有评级,2Q24泰它西普销售略好于预期,但研发费用高于预期","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082016091895a9e1e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082016091895a9e1e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["161027","688331"],"gpt_icon":0},{"id":"2460471710","title":"【港股通】荣昌生物(09995)跌超3% 交银国际削其目标价57.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460471710","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460471710?lang=zh_cn&edition=full","pubTime":"2024-08-20 14:55","pubTimestamp":1724136920,"startTime":"0","endTime":"0","summary":"金吾财讯 | 荣昌生物 震荡走低,截至发稿,跌3.16%,报14.08港元,成交额2130万港元。消息面上,交银国际发研报指,荣昌生物1H24收入同比增长76.5%至7.4亿元,其中泰它西普和维迪西妥销售额分别达到3.8亿/3.5亿元,增长约100%/50%。2)维迪西妥1H24新准入医院超50家,累计准入超300家,UC和GC适应症的DOT分别延长39%/19%,得益于安全性事件管理能力和前线治疗占比提升。目标价由56港元下调至24港元,维持买入评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/MDI1YTMwZTQxYzhhNDE2OTgwYTUxYmYyODYyMzUwODkzNDM3NDk5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MDI1YTMwZTQxYzhhNDE2OTgwYTUxYmYyODYyMzUwODkzNDM3NDk5.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1942645","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSCEI","688331","HSTECH","YANG","09995"],"gpt_icon":1},{"id":"2460042753","title":"港股异动 | 荣昌生物(09995)跌超3% 上半年亏损同比扩大11% 货币资金减少至6.73亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2460042753","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460042753?lang=zh_cn&edition=full","pubTime":"2024-08-20 14:40","pubTimestamp":1724136051,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,荣昌生物跌超3%,截至发稿,跌3.03%,报14.1港元,成交额2010.38万港元。消息面上,荣昌生物近日发布2024年中期业绩,收益7.4亿元,同比增加76.5%;股东应占亏损7.8亿元,同比扩大10.96%。每股基本亏损1.45元。截至2024上半年,荣昌生物账上还剩6.73亿元,同比减少近四成。交银国际研报指出,考虑到目标价暗含65.1%潜在升幅,以及短期催化剂包括商业化产品的逐季放量、泰它西普MG、SS、IgAN 等适应症的关键数据读出和申报,目标价下调至24港元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1166855.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK0239","LU1969619763.USD","LU2328871848.SGD","LU1064130708.USD","BK1583","688331","BK1161","09995","LU2148510915.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2460490150","title":"荣昌生物(688331):商业化产品快速放量 核心管线高效推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2460490150","media":"广发证券股份有...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460490150?lang=zh_cn&edition=full","pubTime":"2024-08-20 13:32","pubTimestamp":1724131976,"startTime":"0","endTime":"0","summary":"公司两款商业化核心产品泰它西普和维迪西妥单抗销售快速放量,利润端亏损扩大主要由于公司加大研发投入推进在研管线,上半年研发费用8.06 亿元。高效拓展营销网络,销售快速放量带动费用率改善。根据公司半年报,截止24 年6 月底,公司已分别组建约800 人自身免疫和近600 人肿瘤科商业化团队,分别准入超过900 家和700 家医院。研发失败风险,产品销售不及预期,市场竞争超预期等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082013330295a959a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082013330295a959a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064131003.USD","LU1064130708.USD","LU2148510915.USD","BK0239","688331"],"gpt_icon":0},{"id":"2460049014","title":"荣昌生物(688331):收入符合预期 核心品种适应症持续拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=2460049014","media":"西南证券股份有...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460049014?lang=zh_cn&edition=full","pubTime":"2024-08-20 13:32","pubTimestamp":1724131968,"startTime":"0","endTime":"0","summary":"核心产品持续放量,准入医院数量再创新高。泰它西普和维迪西妥单抗纳入医保目录后的可及性持续提升。截至2024 年6月30日,自身免疫商业化团队超过800 人,已准入超过900 家医院。泰它西普类风湿性关节炎适应症获NMPA 批准。该试验已于 2023 年第三季度完成首例患者入组。维迪西妥单抗治疗 HER2 阳性存在肝转移的晚期乳腺癌患者的Ⅲ期临床于2024 年6 月达到主要研究终点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082013325295a95993&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082013325295a95993&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064131003.USD","BK0239","688331","LU2148510915.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2460704612","title":"【交银国际:维持荣昌生物“买入”评级 目标价下调至24港元】金十数据8月20日讯,交银国际发表研究报告称,维持荣昌生物(09995.","url":"https://stock-news.laohu8.com/highlight/detail?id=2460704612","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460704612?lang=zh_cn&edition=full","pubTime":"2024-08-20 13:31","pubTimestamp":1724131914,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1169589451.USD","LU1169590202.USD","BK0239","BK1574","09995","BK1583","688331","LU2148510915.USD","LU1064130708.USD","LU1969619763.USD","LU2328871848.SGD","BK4023","PD","BK1161","BK4123","MG","LU1064131003.USD"],"gpt_icon":0},{"id":"2460010654","title":"招银证券:给予荣昌生物(09995.HK)“增持”评级 目标价19.59港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2460010654","media":"同花顺金融研究...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460010654?lang=zh_cn&edition=full","pubTime":"2024-08-20 12:01","pubTimestamp":1724126464,"startTime":"0","endTime":"0","summary":"招银证券8月19日发布公告。Maintain BUY. We expect RC18 and RC48 to maintain strong salesmomentum in China. Nevertheless, consideri ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20240820/c660952694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["161027","688331"],"gpt_icon":0},{"id":"2460223017","title":"交银国际:维持荣昌生物(09995)“买入”评级 目标价下调至24港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2460223017","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460223017?lang=zh_cn&edition=full","pubTime":"2024-08-20 11:46","pubTimestamp":1724125592,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,交银国际发表研究报告称,维持荣昌生物“买入”评级,考虑到目标价暗含65.1%潜在升幅,以及短期催化剂包括商业化产品的逐季放量、泰它西普MG、SS、IgAN 等适应症的关键数据读出和申报,目标价下调至24港元。报告指,2024年上半年公司收入同比增76.5%。公司预计,下半年研发费用将大致与上半年持平,未来研发资源将向近商业化项目及竞争格局较好的早期专目倾斜。公司表示有充足的融资储备支持营运至盈亏平衡。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1166806.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09995","688331"],"gpt_icon":0},{"id":"2460522097","title":"【券商聚焦】交银国际削荣昌生物(09995)目标价57.1% 维持买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2460522097","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460522097?lang=zh_cn&edition=full","pubTime":"2024-08-20 09:00","pubTimestamp":1724115633,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际发研报指,荣昌生物 1H24收入同比增长76.5%至7.4亿元,其中泰它西普和维迪西妥销售额分别达到3.8亿/3.5亿元,增长约100%/50%。该行指,研发费用增长49%至8.1亿元,主要用于泰它西普和维迪西妥的III期临床研究,尤其是泰它西普的海外开发。目标价由56港元下调至24港元,维持买入评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20200908/MTI0OTYzODIzODM=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MTI0OTYzODIzODM=.png"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1942596","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688331","09995"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-03-31","address":"山东省烟台市福山区中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号","stockEarnings":[{"period":"1week","weight":-0.1027},{"period":"1month","weight":-0.0667},{"period":"3month","weight":-0.4806},{"period":"6month","weight":-0.4865},{"period":"1year","weight":-0.5954},{"period":"ytd","weight":-0.6101}],"companyName":"荣昌生物制药(烟台)股份有限公司","boardCode":"AI0027","perCapita":"31185股","boardName":"医药制造业","registeredCapital":"54433万元","compareEarnings":[{"period":"1week","weight":-0.0087},{"period":"1month","weight":-0.0164},{"period":"3month","weight":-0.0759},{"period":"6month","weight":-0.0501},{"period":"1year","weight":-0.0739},{"period":"ytd","weight":-0.0405}],"survey":" 荣昌生物制药(烟台)股份有限公司是一家具有全球化视野的创新型生物制药企业,自成立以来一直专注于抗体药物偶联物(ADC)、抗体融合蛋白、单抗及双抗等治疗性抗体药物领域。公司主营业务是发现、开发与商业化创新、有特色的同类首创(first-in-class)与同类最佳(best-in-class)生物药,以创造药物临床价值为导向,为自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域提供安全、有效、可及的临床解决方案,以满足大量尚未被满足的临床需求。公司的核心产品为泰它西普、维迪西妥单抗、RC28。","serverTime":1724566152513,"listedPrice":48,"stockholders":"5193人(较上一季度减少3.78%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,688331,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}